Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 52024M11628

Prior notification of a concentration (Case M.11628 – PLATINUM EQUITY GROUP / SUNRISE MEDICAL) – Candidate case for simplified procedure

PUB/2024/769

OJ C, C/2024/4912, , ELI: http://data.europa.eu/eli/C/2024/4912/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

ELI: http://data.europa.eu/eli/C/2024/4912/oj

European flag

Official Journal
of the European Union

EN

C series

C/2024/4912

5.8.2024

Prior notification of a concentration

(Case M.11628 – PLATINUM EQUITY GROUP / SUNRISE MEDICAL)

Candidate case for simplified procedure

(Text with EEA relevance)

(C/2024/4912)

1.   

On 29 July 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

—

Platinum Equity Group (US),

—

Cidron Ollopa Investment B.V., Capnor SM AB, Capnor SM2 AB and Sunrise Medical (US) LLC (‘Sunrise Medical’, Germany), indirectly controlled by Nordic Capital’s funds and vehicles.

Platinum Equity Group will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Sunrise Medical.

The concentration is accomplished by way of purchase of shares.

2.   

The business activities of the undertakings concerned are the following:

—

Platinum Equity Group specializes in the merger, acquisition and operation of companies that provide services and solutions to customers in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing and distribution,

—

Sunrise Medical is active in distribution, manufacturing and research and development of mobility solutions for mobility impaired individuals, focusing on manual and power wheelchairs, motorised scooters, seating and positioning systems and daily living aids.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.11628 – PLATINUM EQUITY GROUP / SUNRISE MEDICAL

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1)   OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)   OJ C 160, 5.5.2023, p. 1.

ELI: http://data.europa.eu/eli/C/2024/4912/oj

ISSN 1977-091X (electronic edition)

Top